Integrated BioPharma, Inc., a Delaware corporation together with its subsidiaries, the Company , is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company does business as Chem International, Inc. with certain of its customers and certain vendors. The Company s business segments include: a Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. MDC , which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health care providers b Branded Proprietary Products operated by AgroLabs, Inc. AgroLabs , which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, and c Other Nutraceutical Businesses which includes the operations of i The Vitamin Factory which sells private label MDC products, as well as our AgroLabs products, through the Internet, ii IHT Health Products, Inc. IHT a distributor of fine natural botanicals, including multi minerals produced under a license agreement, iii MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and iv Chem International, Inc., a distributor of certain raw materials for DSM Nutritional Products LLC.
Quote | Integrated Biopharma Inc (OTCMKTS:INBP)
Last: | $0.2196 |
---|---|
Change Percent: | 0.0% |
Open: | $0.2196 |
Close: | $0.2196 |
High: | $0.2196 |
Low: | $0.2196 |
Volume: | 1,000 |
Last Trade Date Time: | 03/27/2024 03:00:00 am |
News | Integrated Biopharma Inc (OTCMKTS:INBP)
HILLSIDE, NJ / ACCESSWIRE / February 12, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ...
Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...
Message Board Posts | Integrated Biopharma Inc (OTCMKTS:INBP)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $INBP News Article - Integrated BioPharma Reports Results for its Quarter and Fiscal Ye | whytestocks | investorshangout | 09/02/2021 6:35:50 PM |
whytestocks: $INBP News Article - Integrated BioPharma Reports Results for its Quarter Ended March 3 | whytestocks | investorshangout | 05/13/2021 7:10:51 PM |
whytestocks: $INBP News Article - Integrated BioPharma Reports Results for its Quarter Ended Decembe | whytestocks | investorshangout | 02/12/2021 8:40:49 PM |
whytestocks: $INBP News Article - OTC Markets Group Welcomes Integrated BioPharma, Inc. to OTCQX | whytestocks | investorshangout | 01/22/2021 9:35:48 PM |
Added few more shares..... | greasemonkeyshoes | investorshub | 02/13/2020 7:46:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Integrated Biopharma Inc Company Name:
INBP Stock Symbol:
OTCMKTS Market:
HILLSIDE, NJ / ACCESSWIRE / February 12, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ...
Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...
HILLSIDE, NJ / ACCESSWIRE / November 9, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2023. Revenue for the quarter ended September 30, 2023 was $12.9 million compared to $12.3 million for the quarter e...